ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

tagmokitug

Also written as “CHS-114” and “Tagmokitug”.

Its studies are mostly in Prostatic Neoplasms · Squamous Cell Carcinoma of Head and Neck · Neoplasm Metastasis, led by Coherus Oncology.

Furthest: phase 2, since Nov 13, 20263 company-led studies, 3 open or runningNext primary completion: Jan 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Coherus Oncology33 open or runningphase 2since Nov 13, 2026Nov 14, 2022Jan 2028phase 1 · NCT06657144

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 14, 2022First study: phase 1 study in Squamous Cell Carcinoma of Head and NeckFirst studyNCT05635643 · 87 enrolled · United States
  2. Oct 23, 2024Phase 1 study in Neoplasm MetastasisNCT06657144 · 154 planned · United States, Taiwan
  3. Nov 13, 2026Phase 2 study in Prostatic NeoplasmsPhase 2 reachedNCT07945821 · 12 planned · United States

Ahead

  1. Jan 2028Primary completion: phase 1 study in Neoplasm MetastasisNCT06657144
  2. Aug 2028Primary completion: phase 2 study in Prostatic NeoplasmsNCT07945821

TargetBeta

CCR8 →read by rule
“A human immunoglobulin G1 (IgG1) afucosylated monoclonal antibody against C-C-chemokine receptor 8 (CCR8), ”NCIt, by rule

Other programs on CCR8

ProgramCompanyFurthest phaseStudies
cafelkibartSino Biopharmaceuticalphase 37
CCR8 Inhibitor IPG7236rulenanjing-immunophage-biotech-co-ltdphase 23
denikitugruleGilead Sciencesphase 23
imzokitugBristol-Myers Squibbphase 22
Anti-CCR8 Antibody-drug Conjugate TAK-188ruleTakedaphase 21
Anti-CCR8 Monoclonal Antibody HC006rulehc-biopharma-incphase 12
azirkitugAbbViephase 11

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07945821Prostatic Neoplasms · United States2RecruitingAug 202812
NCT06657144Neoplasm Metastasis · United States, Taiwan1RecruitingJan 2028154
NCT05635643Squamous Cell Carcinoma of Head and Neck · United States1Active, not recruitingSep 30, 202687

How it is read

Names in the registry

  • “CHS-114”, 2 entries
  • “Tagmokitug”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.